insights_auto
Mengapa FARN turun 4,11%?
Pelajari Lebih Lanjutchevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 35,00
arrow_downward
-4,11%(-1,50) 1 HR
9 Okt, 15.20.22 GMT+1 · GBX
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk FARN...
Pembukaan
GBX 35,00
Tinggi
GBX 38,00
Rendah
GBX 35,00
Kapitalisasi pasar
71,02 jt
Volume rata-rata
45,22 rb
Volume
15,21 rb
Harga tinggi dalam 52 minggu terakhir
GBX 193,58
Harga rendah dalam 52 minggu terakhir
GBX 34,00
EPS
-GBX 0,10
Saham beredar
31,03 jt
Jumlah karyawan
36
Pembukaan
GBX 35,00
Tinggi
GBX 38,00
Rendah
GBX 35,00
Kapitalisasi pasar
71,02 jt
Volume rata-rata
45,22 rb
Volume
15,21 rb
Harga tinggi dalam 52 minggu terakhir
GBX 193,58
Harga rendah dalam 52 minggu terakhir
GBX 34,00
EPS
-GBX 0,10
Saham beredar
31,03 jt
Jumlah karyawan
36
Artikel berita
Dari sumber web dan partner berita
marketscreener.com
·
1 hari yang lalu
Faron agrees bond repayment deferrals for more financial flexibility
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Tentang Faron Pharmaceuticals Oy